Smith-Emery Co., 114 Hunters Pt Blvd, San Francisco, CA 94124, US

Resverlogix Inc is a late-stage clinical biotechnology company based in San Francisco, CA. Founded in 2001, the company focuses on developing safe and effective therapeutics for patients suffering from chronic illnesses. With a strong emphasis on epigenetics, Resverlogix is a global leader in the development of a new class of drugs designed to regulate disease-associated epigenetics, particularly in cardiovascular diseases. Resverlogix's flagship drug, apabetalone, has received Breakthrough Therapy designation from the US FDA, positioning the company at the forefront of modern medicine. Through their science programs and global Phase 3 clinical trial, BETonMACE, Resverlogix aims to provide innovative solutions to key stakeholders, including payer groups, and improve the lives of patients with high unmet medical needs.Generated from the website